Case studies Archives

Application

Application

Inoviem Scientific offers a range of services tailored to the needs of drug discovery, preclinical and clinical development.
We help researchers better meet those requirements essential for the validity of an experiment, accelerate drug development and achieve clinical trial objectives.

Understand the mode of action of your compound

The ultimate understanding of the Mode of Action (MoA) of your compound resides with taking a patient-centric approach

Read more

Validate targets in the study model

Compound pharmacology is always shown in a relevant model, whether cellular or animal. It is important to identify and validate the primary target in the very same model.

Read more

Choose the compound for development

With greater emphasis on translational pharmacology, any number of compounds can be profiled, and we can identify within four weeks of study which one of these offers the best ‘druggability’ to move forward into development.

Read more

Stratify different patient groups

Inoviem harnesses its study power to locate and identify within the whole population the right patient subset who would respond to the compound.

Read more

Identify secondary targets

If you suspect that a secondary target may be problematic, we can quickly identify whether it is beneficial to the indication or produces side-effects.

Read more

Validate target in targeted organism

Our robust empirical approach enables you to salvage a failed compound by finding a new indication for it.

Read more

Define the indication

When your promising compound has failed in its primary indication, we can fast-track you to identifying a condition that would be more efficient.

Read more

Identify biomarkers

Inoviem’s translational pharmacology strategy goes beyond genomic approaches, to give you more information than just the genetic function of a disease.

Read more
Expertise

Our expertise in translational pharmacology

Inoviem offers translational target discovery and drug-target Mode of Action (MoA) based on proprietary label-free technologies developed in a pathological and physiological environment that uses human tissue.

Our approach to working directly on non-modified human tissue means that we eliminate the need for modeling and its significant drawback of failing to take account of the natural environment in which a drug will have its beneficial effect.
We work within a natural environment and provide you with critical data without biasing the drug development process.
This results in a lower risk of drugs reaching the market with unexpected undesired effects or a loss of therapeutic activity.

Our innovative approach:
translational pharmacology

Rather than working on any type of pharmacology in an animal or cellular model, the work is performed directly on human tissue.

Read more

Advantages of approach

Inoviem highly recommends adopting a translational pharmacology strategy at the inception of any project, as it saves time and money.

Read more

How we work with clients

Inoviem develops new methodologies, approaches and/or technologies specifically tailored to solve each client’s unique problem.

Read more
Technology
Technology

As our label-free technologies perform drug-target MoA under physiological environments and in human samples, the test compound preserves its original structure as well as the exact same molecular structure that would be used in therapy.

We provide unbiased information about your drug and its natural environment that helps you find:

The extreme limits of the physiological process

How the physiological process can be modulated

Why the individual is responding to this compound at the molecular level

A description of the pathophysiology of the disease

The differences between the pathology and physiology

Preclinical

Identify the mode of action of your compound

Read more

From preclinical to clinical

Adopt a robust solution that can ensure the success of your Phase II study and accompany you in achieving the success of your drug candidate in Phase III

Read more

Clinical

Identify a cohort of patients responding to your therapy

Read more
Resources
About us
About us

Inoviem, a bioanalytical Contract Research Organization (CRO), enables drug developers to gain greater precision in the understanding of a compound’s clinical Mode of Action (MoA), so that a drug candidate can move rapidly to clinical trials.

Our mission

Our approach is based on the simple idea that current technologies fail to take into account the natural environment in which a drug will have its beneficial effect…

Read more

Our values

Inoviem Scientific’s core values are deeply ingrained in our past, present and future; they guide us in our daily work…

Read more

Our commitment

At Inoviem, we are committed to contributing work that upholds the quality of life and well-being of individuals…

Read more

Our team

Management team

Scientific board

Supervisory board & investors

Read more
Contact us

How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?

Description

Evodiamine as a Macrophage Cholesterol Efflux Enhancer: Interactome Analysis Reveals ABCA1 to be a Direct Binding Target

Isolation of Clozapine targets from rat brain total homogenates

Description

Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertisement".
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
elementor	never	This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assign a randomly generated number to identify unique visitors.
_ga_61RXK9ZCWR	2 years	This cookie is installed by Google Analytics.

Others

Category: Case studies

How to identify Hydroxychloroquine’s ON and OFF targets to design a more potent molecule with enhanced clinical efficacy and reduced retinal toxicity in comparison to HCQ?

Evodiamine as a Macrophage Cholesterol Efflux Enhancer: Interactome Analysis Reveals ABCA1 to be a Direct Binding Target

Isolation of Clozapine targets from rat brain total homogenates

Functional molecular network analysis enables prediction of response to vedolizumab therapy in anti-TNF refractory IBD patients

APPLICATIONS

EXPERTISE

TECHNOLOGY

RESOURCES

ABOUT US

PRIVACY POLICY